# EyePoint Inc. (EYPT) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $4.58, market value $384 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). EyePoint Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 137.7×**. Each dollar of revenue is priced at 137.7×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 11.6×**. The shares trade at 11.6× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -70.6%** (5-yr avg -23.0%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Net margin: -739.4%**. The company reported a net loss over the last twelve months.
- **Return on equity: -75.8%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -107.2%**. Return on all capital, debt included, is -107.2%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -84.2%**. Each dollar of assets produces -84.2% of profit.

## Growth
- **Revenue growth (1 yr): -27.5%** (3-yr -8.8%/yr, 5-yr -1.8%/yr). Revenue fell 27.5% over the last year, against -1.8% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -36.6%**. Earnings per share fell 36.6%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.10**. Debt is 0.10 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.2×**. It would take 0.2 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 8.88** (quick 8.88). Current assets cover the next year's liabilities 8.88 times.
- **Altman Z-score: 4.00**. A Z-score of 4.00 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. EyePoint Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (11 analysts). 11 analysts cover EyePoint Inc.; the consensus is buy, with an average price target of $27.36 (+497% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -61.4%** (YTD -74.9%, 3-mo -61.1%). The shares are down 61.4% over twelve months including dividends.
- **From 52-week high: -76.0%** (15.9% above the low). Trading 76% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 30**. An RSI of 30 is oversold; bounces are common, but oversold can stay oversold in a real decline.
- **Beta (1 yr): 1.03** (volatility 98%). Beta of 1.03 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=EYPT · Page: https://foliofundamentals.com/stocks/eypt

Not investment advice.